• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• Smartbuy

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Hyderabad, June 10

Aurobindo Pharma Ltd received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Zaleplon capsules in 5 mg and 10 mg dosages. The capsules are the generic equivalent of King Pharmaceuticals’ Sonata capsules, which are indicated for the treatment of insomnia. The Hyderabad-based company is in the first line of generics and got the USFDA nod on the very first day post the expiry of the relevant patent. It had already launched the product in the US market, according to a release. Zaleplon was Aurobindo’s 70th Abbreviated New Drug Approval approval from the USFDA, it added. —

Our Bureau

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Bosch Chassis considering hiking offer price for buyback

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line